{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:57:40Z","timestamp":1747184260188,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyse the predictive and prognostic role of clinicopathological parameters in patients with tubo\u2010ovarian carcinoma and malignant effusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective series of 700 malignant peritoneal (<jats:italic>n<\/jats:italic>\u00a0=\u00a0610) and pleural (<jats:italic>n<\/jats:italic>\u00a0=\u00a090) effusions from 558 patients was revised for histotype based on the 2014 World Health Organization criteria. The role of clinicopathological parameters in determining outcome was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority of specimens (597 effusions from 473 patients) were high\u2010grade serous carcinomas (HGSC), followed by low\u2010grade serous carcinoma (LGSC; 48 effusions, 37 patients), clear cell carcinoma (CCC; 23 effusions, 19 patients) and carcinosarcoma (CS; 16 effusions, 16 patients). Patients with CCC and CS had the shortest, those with HGSC intermediate, and those with LGSC longest overall and progression\u2010free survival (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). For patients with HGSC, older age (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002), more advanced FIGO stage (IV vs III; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), delayed\/no surgery (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), larger residual disease volume (RD; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), non\u2010complete response to chemotherapy at diagnosis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and primary platinum resistance (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were associated with shorter overall survival. In Cox multivariate analysis, FIGO stage (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002) and primary platinum resistance (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were independent prognosticators. Significant association was additionally found for parameters analysed for progression\u2010free survival in HGSC (previous chemotherapy: <jats:italic>P<\/jats:italic>\u00a0=\u00a00.029; age: <jats:italic>P<\/jats:italic>\u00a0=\u00a00.046; FIGO stage, upfront therapy, RD: <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), of which previous chemotherapy, upfront therapy, and RD were independent prognosticators (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The vast majority of malignant effusions in patients with tubo\u2010ovarian carcinoma are derived from serous carcinoma or related tumours, such as CS. Histology is a powerful prognostic factor in this patient group, as are established clinical parameters.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cyt.13126","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T10:59:12Z","timestamp":1649588352000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological prognostic parameters in patients with tubo\u2010ovarian carcinoma effusions"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8427","authenticated-orcid":false,"given":"Ben","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Pathology Norwegian Radium Hospital Oslo University Hospital  Oslo Norway"},{"name":"Faculty of Medicine Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari Bunkholt","family":"Elstrand","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Norwegian Radium Hospital Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"volume-title":"WHO Classification of Tumuors of Female Reproductive Organs","year":"2014","author":"Kurman RJ","key":"e_1_2_9_3_1"},{"volume-title":"Female Genital Tumours. WHO Classification of Tumours","year":"2020","author":"WHO Classification of Tumours Editorial Board","key":"e_1_2_9_4_1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13248"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-76478-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.032"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.01.539"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002023"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.05.036"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.06.018"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051336"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.06.033"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806"},{"issue":"7","key":"e_1_2_9_16_1","first-page":"CD005343","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","volume":"7","author":"Coleridge SL","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2018.05.003"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.13126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cyt.13126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.13126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T20:47:36Z","timestamp":1692823656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cyt.13126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/cyt.13126"],"URL":"https:\/\/doi.org\/10.1111\/cyt.13126","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"type":"print","value":"0956-5507"},{"type":"electronic","value":"1365-2303"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"2022-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}